Introduction
============

Hemorrhagic transformation (HT) is a common complication of ischemic stroke in patients receiving recanalization therapy \[[@r1]\] that results in worse outcomes and delays the initiation of antiplatelet or anticoagulation therapy \[[@r2]\]. HT results from damage to the blood-brain barrier and extravasation of blood over impaired cerebral vessels in acute ischemic stroke (AIS) \[[@r3],[@r4]\]. Previous investigators reported that the risk of HT and symptomatic intracranial hemorrhage was associated with old age, hypertension, reduced platelet count, large infarct, reperfusion time and thrombolytic treatment \[[@r5]--[@r7]\]. However, the association between serum lipids and HT remains deeply controversial.

Several studies have reported that low levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) increase the incidence of cerebral hemorrhage \[[@r8]\] and HT after AIS \[[@r9],[@r10]\], while others have observed no association between cholesterol level and HT \[[@r11],[@r12]\]. Our prior studies have shown that low values of triglyceride (TG) and TG/high-density lipoprotein cholesterol (HDL-C) are independently associated with mortality and poor outcome in AIS patients \[[@r13]--[@r15]\]. Nevertheless, whether low levels of TG/HDL-C can increase the incidence of HT after AIS remains elusive.

The current study enrolled two independent cohorts of a total of 1981 AIS patients to explore the accurate effect of TG/HDL-C on HT after AIS, and we found that low levels of TG/HDL-C were correlated with HT in patients with AIS attributable to large artery atherosclerosis (LAA). Additionally, several nomograms have been successfully established to predict disease prognostics, but nomograms for assessing HT after AIS are scarce. Hence, we investigated the predictive power of a nomogram based on TG/HDL-C in AIS patients.

RESULTS
=======

General characteristics
-----------------------

The general characteristics of the training and test cohorts are detailed in [Tables 1, 2 and 3](#t1){ref-type="table"}[](#t2){ref-type="table"}[](#t3){ref-type="table"}. A total of 950 (66.76%) men and 473 (33.24%) women were enrolled in the training cohort. The median National Institute of Health stroke scale (NIHSS) score was 4. The mean±SD of triglyceride (TG), TC, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and TG/HDL-C values were as follows: 1.56±1.16 mmol/L for TG, 4.41±1.09 mmol/L for TC, 1.09±0.41 mmol/L for HDL-C, 2.66±0.83 mmol/L for LDL-C, and 1.60±1.44 for TG/HDL-C ([Table 1](#t1){ref-type="table"}). Baseline characteristics of the training cohort according to stroke etiology are detailed in [Table 2](#t2){ref-type="table"}. Data from an additional 558 patients attributable to LAA were retrospectively recruited into the test cohort. The median NIHSS score was 4. The baseline characteristics and mean concentrations of serum lipids are shown in [Table 3](#t3){ref-type="table"}.

###### Baseline characteristics of the training cohort according to the presence of hemorrhagic transformation.

  -------------------------------- ---------------- ------------------ ------------------ ---------
  Baseline characteristics         Total (n=1423)   Absence (n=1268)   Presence (n=155)   *P*
  Demographics                                                                            
  Sex (male)                       950 (66.76)      851 (67.11)        99 (63.87)         0.419
      Age (years)                  68.21±12.17      67.88±12.00        70.84±13.23        0.004
  Weight (kg)                      67 (60-75)       67 (60-75)         65 (60-75)         0.985
  Height (cm)                      165.60±7.87      165.61±7.85        165.51±8.12        0.893
  Clinical characteristics                                                                
  Smoking                          560 (39.35)      515 (40.62)        45 (29.03)         0.005
  SBP (mm Hg)                      144.52±20.80     143.88±20.64       149.77±21.45       0.001
  DBP (mm Hg)                      80 (80-90)       80 (80-92)         82 (78-98)         0.114
  NIHSS on admission               3 (2-6)          3 (2-5)            8 (2-15)           \<0.001
  Medical history                                                                         
  Hypertension                     1044 (73.37)     930 (73.34)        114 (73.55)        0.957
  Diabetes mellitus                286 (21.5)       245 (19.32)        41 (26.45)         0.037
      Coronary artery disease      160 (11.24)      135 (10.65)        25 (16.13)         0.041
  History of atrial fibrillation   168 (11.81)      117 (9.23)         51 (32.90)         \<0.001
  Previous TIA                     227 (15.95)      198 (15.62)        29 (18.71)         0.321
  Stroke etiology ^a^                                                                     \<0.001
  LAA                              722 (50.74)      660 (52.05)        62 (40.00)         
  Cardioembolism                   189 (13.28)      130 (10.25)        59 (38.06)         
      Small-vessel occlusion       463 (32.54)      438 (34.54)        25 (16.13)         
  Undetermined/unclassified        49 (3.44)        40 (2.81)          9 (5.81)           
  Prior use of antiplatelets       409 (28.74)      353 (27.84)        56 (36.13)         0.031
  Prior use of anticoagulants      124 (8.71)       106 (8.36)         18 (11.61)         0.175
  Laboratory characteristics                                                              
      Fasting glucose (mmol/L)     6.19±2.54        6.13±2.44          6.61±3.23          0.030
  Platelet (10^9^/L)               197.97±59.27     199.38±59.49       186.61±56.32       0.012
  INR                              0.98±0.19        0.97±0.20          1.00±0.13          0.051
  BUN (mmol/L)                     5.94±2.46        5.91±2.47          6.22±2.34          0.128
  Creatinine (μmol/L)              80.74±56.09      80.74±58.44        80.77±31.08        0.994
  TG (mmol/L)                      1.56±1.16        1.60±1.18          1.18±0.82          \<0.001
      TC (mmol/L)                  4.41±1.09        4.44±1.09          4.17±1.09          0.004
  HDL-C (mmol/L)                   1.09±0.41        1.09±0.42          1.14±0.29          0.160
  LDL-C (mmol/L)                   2.66±0.83        2.68±0.83          2.50±0.83          0.012
  TG/HDL-C                         1.60±1.44        1.65±1.46          1.16±1.09          \<0.001
  Uric acid (μmol/L)               321.90±107.74    324.05±107.14      305.14±111.25      0.056
  HbA1c (%)                        6.57±1.63        6.57±1.63          6.52±1.60          0.691
  CRP (μg/mL)                      8.10±18.85       7.80±19.29         10.41±14.85        0.175
  HCY (μmol/L)                     17.16±8.89       17.22±9.08         16.69±7.23         0.517
      Lp-PLA2 (ng/mL)              180 (127-267)    178 (127-266)      190 (135-300)      0.173
  -------------------------------- ---------------- ------------------ ------------------ ---------

LAA, large artery atherosclerosis; SBP, systolic blood pressure; DBP, diastolic blood pressure; NIHSS, National Institute of Health Stroke Scale; TIA, transient ischemic attack; INR, International Normalized Ratio; BUN, blood urea nitrogen; CRP, C-reactive protein; HCY, homocysteine; Lp-PLA2, lipoprotein-associated phospholipase A2; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG/HDL-C, TG to HDL-C ratio.

Categorical variables were expressed as frequencies and percentages and were compared by the Chi-squared test. Continuous variables were expressed as the means ± standard deviations (S.D.) or medians (interquartile ranges, IQR), which were compared by the Student's t test, one-way ANOVA or the Mann--Whitney U-test if necessary.

^a^ According to the modified TOAST classification.

###### Baseline characteristics of the training cohort according to stroke etiology.

  -------------------------------- ----------------- ------------------------ -------------------------------- ----------------- --------------- ----------------- ----------------- --------------- -------
  Baseline characteristics         LAA (n=722)       Cardioembolism (n=190)   Small-vessel occlusion (n=463)                                                                                         
  Absence (n=660)                  Presence (n=62)   *P*                      Absence (n=130)                  Presence (n=60)   *P*             Absence (n=438)   Presence (n=25)   *P*             
  Demographics                                                                                                                                                                                       
  Sex (male)                       463 (70.15)       47 (75.81)               0.350                            63 (48.46)        29 (48.33)      0.987             301 (68.72)       17 (68.00)      0.940
     Age (years)                   68 (61-76)        70 (55-81)               0.640                            76 (67-83)        78 (73.5-83)    0.102             67 (59-75)        65 (62-72)      0.774
  Weight (kg)                      67.69±11.29       68.52±13.36              0.174                            65.17±10.71       65.68±13.93     0.797             67.84±11.19       65.57±10.35     0.342
  Height (cm)                      165.63±7.22       166.91±7.83              0.696                            164.27±7.78       164.06±8.99     0.872             165.94±7.93       165.33±6.75     0.716
  Clinical characteristics                                                                                                                                                                           
  Smoking                          270               25                       0.928                            27                7               0.128             200 (45.66)       11 (44.00)      0.871
  SBP (mm Hg)                      144.93±20.68      150.89±20.83             0.045                            141.32±21.06      151.33±20.81    0.003             143.19±20.09      145.72±24.70    0.619
  DBP (mm Hg)                      80 (80-90)        82 (80-99)               0.342                            84.85±13.73       85.97±15.17     0.614             84.84±11.57       87.52±16.46     0.429
  NIHSS on admission               3 (2-6)           5 (2-12)                 0.006                            9 (3-15)          16 (10-19)      0.001             2 (1-4)           2 (1-3)         0.569
  Medical history                                                                                                                                                                                    
  Hypertension                     510 (77.27)       49 (79.03)               0.751                            88 (67.69)        45 (75.00)      0.307             307 (70.09)       16 (64.00)      0.519
  Diabetes mellitus                179 (27.12)       28 (45.16)               0.003                            23 (17.69)        15 (25.00)      0.242             135 (30.82)       4 (16.00)       0.116
     Coronary artery disease       64 (9.70)         5 (8.06)                 0.676                            28 (21.54)        14 (23.33)      0.782             36 (8.22)         4 (16.00)       0.259
  History of atrial fibrillation   17 (2.58)         4 (6.45)                 0.083                            91 (70.00)        43 (71.67)      0.815             5 (1.14)          1 (4.00)        0.749
  Previous TIA                     122 (18.48)       11 (17.74)               0.885                            25 (19.23)        12 (20.00)      0.901             45 (10.27)        4 (16.00)       0.365
  Prior use of antiplatelets       242 (36.67)       26 (41.94)               0.411                            18 (13.85)        8 (13.33)       0.924             92 (21.00)        9 (36.00)       0.077
  Prior use of anticoagulants      15 (2.27)         4 (6.45)                 0.049                            68 (52.31)        24 (40.00)      0.115             3 (0.68)          0 (0.00)        0.386
  Laboratory characteristics                                                                                                                                                                         
     Fasting glucose (mmol/L)      6.28±2.61         6.20±2.27                0.825                            6.05±1.89         7.61±4.23       0.001             5.92±2.33         5.31±1.91       0.207
  Platelet (10^9^/L)               202.78±60.99      201.10±61.42             0.835                            181.87±58.68      169.66±49.45    0.168             199.33±56.56      193.72±39.37    0.506
  INR                              0.96±0.15         0.99±0.10                0.128                            1.12±0.47         1.04±0.16       0.092             0.95±0.08         0.94±0.07       0.778
  BUN (mmol/L)                     5.95±2.44         6.23±2.31                0.389                            6.24±2.84         6.48±2.48       0.577             5.67±2.07         5.53±1.83       0.744
  Creatinine (μmol/L)              81.21±58.44       81.24±26.86              0.996                            81.23±29.87       82.10±35.44     0.861             78.37±55.39       76.36±27.73     0.857
  TG (mmol/L)                      1.66±1.31         1.24±0.85                0.016                            1.19±0.68         1.07±0.53       0.096             1.66±1.10         1.30±1.27       0.114
     TC (mmol/L)                   4.50±1.17         4.28±1.21                0.159                            4.21±0.94         3.97±0.96       0.099             4.44±1.00         4.30±0.74       0.487
  HDL-C (mmol/L)                   1.08±0.50         1.08±0.27                0.991                            1.18±0.43         1.21±0.30       0.662             1.07±0.26         1.10±0.31       0.546
  LDL-C (mmol/L)                   2.72±0.87         2.61±0.88                0.329                            2.51±0.75         2.30±0.76       0.075             2.68±0.77         2.62±0.71       0.705
  TG/HDL-C                         1.71±1.21         1.33±0.97                0.006                            1.15±0.84         1.06±0.55       0.105             1.71±1.39         1.48±1.99       0.428
  Uric acid (μmol/L)               319.83±106.31     309.21±108.40            0.483                            351.25±124.47     316.17±117.09   0.071             312.59±98.39      284.50±106.06   0.126
  HbA1c (%)                        6.72±1.72         6.62±1.58                0.649                            6.22±1.33         6.74±1.87       0.144             6.47±1.57         5.93±0.91       0.090
  CRP (μg/mL)                      7.42±13.61        11.15±18.34              0.095                            9.81±12.69        10.56±11.48     0.738             7.84±27.67        7.95±15.46      0.988
  HCY (μmol/L)                     17.08±8.92        17.63±8.46               0.661                            18.18±9.91        16.30±6.71      0.214             17.11±9.10        14.82±3.88      0.288
     Lp-PLA2 (ng/mL)               213.93±137.28     224.79±137.00            0.602                            244.04±140.23     258.92±148.88   0.535             204.97±118.94     183.72±93.68    0.444
  -------------------------------- ----------------- ------------------------ -------------------------------- ----------------- --------------- ----------------- ----------------- --------------- -------

LAA, large artery atherosclerosis; SBP, systolic blood pressure; DBP, diastolic blood pressure; NIHSS, National Institute of Health Stroke Scale; TIA, transient ischemic attack; INR, International Normalized Ratio; BUN, blood urea nitrogen; CRP, C-reactive protein; HCY, homocysteine; Lp-PLA2, lipoprotein-associated phospholipase A2; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG/HDL-C, TG to HDL-C ratio.

Categorical variables were expressed as frequencies and percentages and were compared by the Chi-squared test. Continuous variables were expressed as the means ± standard deviations (S.D.) or medians (interquartile ranges, IQR), which were compared by the Student's t test, one-way ANOVA or the Mann--Whitney U-test if necessary.

###### Baseline characteristics of the test cohort according to the presence of hemorrhagic transformation.

  -------------------------------- ----------------- --------------- ---------
  Baseline characteristics         LAA (n=558)                       
  Absence (n=508)                  Presence (n=50)   *P*             
  Demographics                                                       
      Sex (male/female)            318 (62.60)       36 (72.00)      0.188
      Age (years)                  70 (60-78)        66 (57-77)      0.016
      Weight (kg)                  68.92±9.91        68.77±9.03      0.547
      Height (cm)                  167.54±6.46       166.09±7.94     0.138
  Clinical characteristics                                           
  Smoking                          171 (33.66)       18 (36.00)      0.739
  SBP (mm Hg)                      140.08±16.29      153.22±18.74    \<0.001
  DBP (mm Hg)                      82.54±13.02       81.00±12.76     0.624
  NIHSS on admission               3 (2-5)           6 (3-13)        \<0.001
  Medical history                                                    
  Hypertension                     358 (70.47)       31 (62.00)      0.213
  Diabetes mellitus                124 (24.41)       21 (42.00)      0.007
      Coronary artery disease      37 (7.28)         4 (8.00)        0.853
  History of atrial fibrillation   16 (3.15)         4 (8.00)        0.078
  Previous TIA                     74 (14.57)        11 (22.00)      0.163
  Prior use of antiplatelets       129 (25.39)       15 (30.00)      0.478
  Prior use of anticoagulants      10 (1.97)         3 (6.00)        0.071
  Laboratory characteristics                                         
      Fasting glucose (mmol/L)     5.78±2.09         6.26±2.24       0.123
  Platelet (10^9^/L)               189.02±68.91      190.28±63.74    0.802
  INR                              0.89±0.13         0.92±0.18       0.135
      BUN (mmol/L)                 6.10±2.25         5.92±2.10       0.578
  Creatinine (μmol/L)              76.08±28.00       81.54±29.43     0.194
      TG (mmol/L)                  1.75±1.29         1.28±0.96       \<0.001
      TC (mmol/L)                  4.76±1.11         4.70±1.24       0.724
  HDL-C (mmol/L)                   1.15±0.28         1.25±0.37       0.021
  LDL-C (mmol/L)                   2.80±0.81         2.69±0.94       0.265
  TG/HDL-C                         1.82±1.14         1.29±1.27       0.002
  Uric acid (μmol/L)               302.06±97.15      312.44±90.37    0.485
      HbA1c (%)                    6.23±1.59         6.44±1.52       0.370
  CRP (μg/mL)                      7.05±12.31        9.80±17.66      0.157
  HCY (μmol/L)                     18.20±9.12        18.87±12.76     0.633
      Lp-PLA2 (ng/mL)              192.90±124.16     220.01±108.29   0.137
  -------------------------------- ----------------- --------------- ---------

LAA, large artery atherosclerosis; SBP, systolic blood pressure; DBP, diastolic blood pressure; NIHSS, National Institute of Health Stroke Scale; TIA, transient ischemic attack; INR, International Normalized Ratio; BUN, blood urea nitrogen; CRP, C-reactive protein; HCY, homocysteine; Lp-PLA2, lipoprotein-associated phospholipase A2. TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG/HDL-C, TG to HDL-C ratio.

Categorical variables were expressed as frequencies and percentages and were compared by the Chi-squared test. Continuous variables were expressed as the means ± standard deviations (S.D.) or medians (interquartile ranges, IQR), which were compared by the Student's t test, one-way ANOVA or the Mann--Whitney U-test if necessary.

Correlation of lipid level with HT
----------------------------------

For the training cohort, HT after AIS was observed in 155 (10.89%) patients. Comparisons of baseline characteristics in patients with or without HT are shown in [Table 1](#t1){ref-type="table"}. Compared with patients without HT, patients with HT had higher proportions of no smoking, diabetes mellitus, coronary artery disease, atrial fibrillation and prior use of antiplatelets and anticoagulants; elder age; higher levels of SBP and fasting glucose; lower levels of platelets, TG, TC, LDL-C and TG/HDL-C; and higher scores of NIHSS (all *P*\<0.05). The distributions of Trial of Org 10172 in Acute Stroke Treatment (TOAST) classifications in patients in the absence and presence of HT were significantly different (*P*\<0.001) ([Table 1](#t1){ref-type="table"}). Furthermore, HT was more frequent in cardioembolism (38.06%) than in other TOAST classifications ([Table 1](#t1){ref-type="table"}), as previously depicted \[[@r16],[@r17]\]. In patients attributable to LAA, HT was more likely to be present if the patients had diabetes mellitus (*P*=0.003) and prior use of anticoagulants (*P*=0.049), higher scores on the NIHSS (*P*=0.006), or lower levels of TG (*P*=0.016) and TG/HDL-C (*P*=0.006) ([Table 2](#t2){ref-type="table"}). In patients with cardioembolism, HT correlated significantly with NIHSS score on admission (*P*=0.001) and with fasting glucose (*P*=0.001) as well as systolic blood pressure (SBP) (*P*=0.045), but not with lipid level ([Table 2](#t2){ref-type="table"}). However, baseline characteristics showed no correlation with the incidence of HT in patients with small-vessel occlusion ([Table 2](#t2){ref-type="table"}). For the test cohort, HT occurred in 50 (8.96%) patients. Similar results were observed in patients attributable to LAA ([Table 3](#t3){ref-type="table"}).

A novel predictive model
------------------------

The univariate logistic regression analyses for baseline characteristics in the training cohort are shown in [Tables 4](#t4){ref-type="table"} and [Table S1](#SD1){ref-type="supplementary-material"}. The results showed that age, smoking, SBP, NIHSS scores, diabetes mellitus, coronary artery disease, atrial fibrillation, stroke etiology, prior use of antiplatelets, fasting glucose, platelets, TG, TC, LDL-C and TG/HDL-C were associated with HT (all *P*\<0.05) ([Table 4](#t4){ref-type="table"}). The multivariable logistic regression analyses showed that patients attributable to cardioembolism had higher risk of HT than those attributable to LAA (OR=3.03, 95%CI=1.91-4.80, *P*\<0.001); however, TG, TC, LDL-C and TG/HDL-C were not independently associated with HT in patients attributable to cardioembolism (*P*\>0.05). To further investigate the association of stroke etiology with HT, we performed logistic regression analyses in patients attributable to LAA, cardioembolism and small-vessel occlusion. The findings indicated that lower levels of TG (OR= 0.61, 95%CI=0.27-0.98, *P*=0.042) and TG/HDL-C (OR= 0.53, 95%CI=0.20-0.93, *P*=0.032) were significantly associated with a higher risk of HT in patients with LAA ([Table 4](#t4){ref-type="table"}), but not in patients with cardioembolism or small-vessel occlusion ([Table S1](#SD1){ref-type="supplementary-material"}). These results were further confirmed in the test cohort of patients with LAA ([Table 4](#t4){ref-type="table"}).

###### Univariate and multivariate analyses for the potential prognostic factors associated with hemorrhagic transformation by logistic regression model.

  -------------------------------- ----------------------- --------------------- ----------------------- --------------------- ----------------------- ----------- ----------- ------------------ -----------
  **Baseline characteristics**     Training cohort         Test cohort                                                                                                                            
  All patients                     LAA                     LAA                                                                                                                                    
  Univariate analysis              Multivariate analysis   Univariate analysis   Multivariate analysis   Univariate analysis   Multivariate analysis                                              
  Demographic characteristics      *P* value               OR (95%CI)^a^         *P* value               *P* value             OR (95%CI)^b^           *P* value   *P* value   OR (95%CI)^c^      *P* value
     Sex (male)                    0.419                   \-                    \-                      0.351                 \-                      \-          0.742       \-                 \-
     Age (years)                   0.004                   1.00 (0.98-1.01)      0.568                   0.589                 \-                      \-          0.040       1.11 (0.82-1.32)   0.144
  Weight (kg)                      0.983                   \-                    \-                      0.174                 \-                      \-          0.308       \-                 \-
  Height (cm)                      0.893                   \-                    \-                      0.244                 \-                      \-          0.516       \-                 \-
  Clinical characteristics                                                                                                                                                                        
  Smoking (yes)                    0.006                   0.91 (0.59-1.39)      0.648                   0.928                 \-                      \-          0.411       \-                 \-
  SBP (mm Hg)                      0.001                   1.01 (1.00-1.02)      0.006                   0.032                 1.06 (0.83-1.36)        0.630       0.005       1.00 (0.77-1.32)   0.880
  DBP (mm Hg)                      0.114                   \-                    \-                      0.265                 \-                      \-          0.198       \-                 \-
  NIHSS on admission               \<0.001                 1.06 (1.03-1.09)      \<0.001                 \<0.001               1.05 (1.01-1.10)        0.026       \<0.001     1.14 (1.01-1.38)   \<0.001
  Medical history                                                                                                                                                                                 
  Hypertension                     0.957                   \-                    \-                      0.751                 \-                      \-          0.428       \-                 \-
  Diabetes mellitus                0.033                   1.42 (0.91-2.20)      0.119                   0.003                 1.21 (1.04-1.41)        0.012       \<0.001     1.86 (1.17-3.25)   \<0.001
     Coronary artery disease       0.043                   1.00 (0.58-1.71)      0.988                   0.676                 \-                      \-          0.546       \-                 \-
  History of atrial fibrillation   \<0.001                 1.56 (0.86-2.83)      0.147                   0.094                 \-                      \-          0.095       \-                 \-
  Previous TIA                     0.321                   \-                    \-                      0.885                 \-                      \-          0.612       \-                 \-
  Stroke etiology ^a^              \<0.001                                                                                                                                                        
  LAA                                                      reference             \-                      \-                    \-                      \-          \-          \-                 \-
  Cardioembolism                                           3.03 (1.91-4.80)      \<0.001                 \-                    \-                      \-          \-          \-                 \-
     Small-vessel occlusion                                0.75 (0.45-1.23)      0.266                   \-                    \-                      \-          \-          \-                 \-
  Undetermined/unclassified                                1.84 (0.81-4.20)      0.149                   \-                    \-                      \-          \-          \-                 \-
  Prior use of antiplatelets       0.047                   1.10 (0.81-1.69)      0.338                   0.514                 \-                      \-          0.191       \-                 \-
  Prior use of anticoagulants      0.246                   \-                    \-                      0.050                 \-                      \-          0.082       \-                 \-
  Laboratory characteristics                                                                                                                                                                      
     Fasting glucose (mmol/L)      0.032                   1.05 (0.98-1.13)      0.188                   0.825                 \-                      \-          0.668       \-                 \-
  Platelet (10^9^/L)               0.012                   1.00 (0.99-1.00)      0.603                   0.508                 \-                      \-          0.552       \-                 \-
  INR                              0.072                   \-                    \-                      0.186                 \-                      \-          0.257       \-                 \-
  BUN (mmol/L)                     0.130                   \-                    \-                      0.389                 \-                      \-          0.090       \-                 \-
  Creatinine (μmol/L)              0.994                   \-                    \-                      0.996                 \-                      \-          0.946       \-                 \-
  TG (mmol/L)                      \<0.001                 0.76 (0.61-1.15)      0.204                   0.027                 0.61 (0.27-0.98)        0.042       0.010       0.72 (0.68-0.97)   0.023
     TC (mmol/L)                   0.004                   0.79 (0.66-1.04)      0.058                   0.158                 \-                      \-          0.106       \-                 \-
  HDL-C (mmol/L)                   0.068                   \-                    \-                      0.991                 \-                      \-          0.044       1.05 (0.50-1.03)   0.094
  LDL-C (mmol/L)                   0.012                   0.79 (0.63-1.01)      0.063                   0.328                 \-                      \-          0.100       \-                 \-
  TG/HDL-C                         \<0.001                 0.64 (0.49-1.64)      0.593                   0.015                 0.53 (0.20-0.93)        0.032       \<0.001     0.60 (0.45-0.93)   0.011
  Uric acid (μmol/L)               0.058                   \-                    \-                      0.482                 \-                      \-          0.095       \-                 \-
  HbA1c (%)                        0.691                   \-                    \-                      0.649                 \-                      \-          0.512       \-                 \-
  CRP (μg/mL)                      0.207                   \-                    \-                      0.108                 \-                      \-          0.224       \-                 \-
  HCY (μmol/L)                     0.517                   \-                    \-                      0.661                 \-                      \-          0.313       \-                 \-
     Lp-PLA2 (ng/mL)               0.174                   \-                    \-                      0.602                 \-                      \-          0.177       \-                 \-
  -------------------------------- ----------------------- --------------------- ----------------------- --------------------- ----------------------- ----------- ----------- ------------------ -----------

LAA, large artery atherosclerosis; SBP, systolic blood pressure; DBP, diastolic blood pressure; NIHSS, National Institute of Health Stroke Scale; TIA, transient ischemic attack; INR, International Normalized Ratio; BUN, blood urea nitrogen; CRP, C-reactive protein; HCY, homocysteine; Lp-PLA2, lipoprotein-associated phospholipase A2; TG, triglyceride; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG/HDL-C, TG to HDL-C ratio.

^a^ According to the modified TOAST classification.

-, not available.

^a^OR, adjusted for age, smoking, SBP, NIHSS on admission, diabetes mellitus, coronary artery disease, history of atrial fibrillation, stroke etiology, prior use of antiplatelets, fasting glucose and platelet; ^b^OR, adjusted for SBP, NIHSS on admission and diabetes mellitus; ^c^OR, age, SBP, NIHSS on admission and diabetes mellitus.

To investigate the predictive power of lipid level for HT in patients with LAA, we established a nomogram according to the results from univariable analyses to predict the incidence of HT. The univariable analyses showed that NIHSS scores on admission, diabetes mellitus, TG and TG/HDL-C were associated with HT in the training and test cohort patients with LAA. Furthermore, TG/HDL-C had the greatest AUC among lipid classifications, and NIHSS scores on admission, diabetes mellitus, and TG/HDL-C were included in the nomogram for both the training ([Figure 1A](#f1){ref-type="fig"}) and test ([Figure 1B](#f1){ref-type="fig"}) cohorts by stepwise logistic regression analyses. The novel models for both cohorts indicated that higher NIHSS scores, diabetes mellitus and lower TG/HDL-C were indicators of HT in patients with LAA. These findings were similar to those obtained previously in the multivariate logistic models.

![**Nomograms of patients attributable to large artery atherosclerosis to predict hemorrhagic transformation after acute ischemic stroke.** Locate the TG/HDL-C on the respective axis; draw a straight line up to the Points axis to determine how many points toward hemorrhagic transformation the patient receives for the TG/HDL-C; repeat this process for diabetes mellitus and NIHSS; add the points and locate this number on the Total points axis; and draw a straight line down to find the patient's estimated risk of hemorrhagic transformation. The c-indexes for the training and test cohorts of patients attributable to large artery atherosclerosis are 0.734 (**A**) and 0.698 (**B**), respectively. TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; NIHSS, National Institute of Health Stroke Scale.](aging-11-101859-g001){#f1}

Predictive values of TG, TG/HDL-C for HT
----------------------------------------

To study the predictive power of TG and TG/HDL-C, we performed ROC curves and AUC analyses regarding HT in patients attributable to LAA from the training cohort. We also analyzed the combined predictive value of TG and HDL-C for HT. The results showed that the predictive value of TG/HDL-C (AUC=0.77, 95%CI=0.72-0.81) was significantly superior to TG (AUC=0.68, 95%CI=0.63-0.72) and their combined effect (AUC=0.67, 95%CI=0.62-0.71) ([Figure 2A](#f2){ref-type="fig"}). In addition, similar findings were observed when their predictive power was further analyzed by ROC curves and AUC analyses in patients attributable to LAA of the test cohort ([Figure 2B](#f2){ref-type="fig"}).

![**Predictive power of TG, HDL-C, TG+HDL-C, and TG/HDL-C for hemorrhagic transformation in patients attributable to large artery atherosclerosis of the training** (**A**) and test (**B**) cohorts.](aging-11-101859-g002){#f2}

DISCUSSION
==========

Using the training cohort from a prospective consecutive hospital-based stroke registry in Nanjing First Hospital, we observed no independent correlation between lower LDL-C and HT but confirmed an association of lower TG/HDL-C with a high incidence of HT in patients attributable to LAA, but not cardioembolism and small-vessel occlusion. The significant association was further supported in the test cohort. The predictive power of TG/HDL-C for HT was superior to that of the other serum lipids. The nomograms further confirmed the potential significance of TG/HDL-C for predicting the incidence of HT in patients with LAA.

There has been a long-standing dispute regarding the increased risk of cerebral hemorrhage at lower levels of serum lipids. Several studies have reported that low cholesterol level was not associated with hemorrhagic stroke \[[@r18],[@r19]\]. Others have stated a positive correlation of cerebral hemorrhage and low cholesterol level \[[@r8]\]. Lipid-lowering treatment with 80 mg atorvastatin has been shown to increase hemorrhagic stroke \[[@r20]\].

The underlying molecular mechanisms of the increase in cerebral hemorrhages at low levels of cholesterol remain unclear. Some investigators have suggested that adequate cholesterol levels may maintain the integrity of cerebral small vessels \[[@r21]\] and that immunoliposome may ameliorate endothelial damage and reduce HT after thrombolysis \[[@r22]\]. Therefore, low levels of TG may increase the incidence of HT by injuring cerebral vessel integrity.

LAA is a central subtype of the TOAST classification system. A previous report found that, among patients with ischemic stroke, LAA was the cause for 12% to 54%, and cardioembolism was the cause for 10-26% \[[@r23]\]. In the current study, LAA accounted for 50.74% in the training cohort. A major point distinguishing LAA from cardioembolism is stenosis of the proximal cerebral large artery, which may disturb relevant cerebral neurovascular units in various pathways. Furthermore, the microemboli increase the cerebral arterial stenosis, which results in a low perfusion state in the cerebrum \[[@r24],[@r25]\]. However, cardioembolism indicates heart-originating embolism without significant cerebral arterial stenosis \[[@r26]\]. Hence, the cardioembolism could not induce long-standing subclinical damage for intact neurovascular units. Cerebral vessels of LAA patients, exposed to proximal arterial stenosis in the hemorrhage-prone state of low cholesterol, tend to increase the incidence of HT \[[@r17]\].

The TG/HDL-C was first reported to be associated with the presence of insulin resistance \[[@r28]\]. Subsequently, TG/HDL-C predicted cardiovascular events in hypertension and diabetes mellitus \[[@r29],[@r30]\]. Our previous study indicated that low levels of TG/HDL-C were associated with mortality and worse short-term outcomes after AIS \[[@r14],[@r15]\]. This study has further shown that low levels of TG/HDL-C increased the risk of HT in patients attributable to LAA in two independent cohorts. Although there was a lower proportion of smoking in AIS patients with HT, as shown in [Table 1](#t1){ref-type="table"}, subgroup analyses by stroke etiology showed that smoking did not impact the incidence of HT in AIS patients of both cohorts. Additionally, the findings from nomograms by stepwise logistic regression analyses suggested that NIHSS on admission, diabetes mellitus and TG/HDL-C were also predictors of HT in the training and test cohorts, which further supported the results from multivariate logistic regression analyses. The predictive capacity of our nomogram was superior to that of NIHSS scores on admission. Therefore, TG/HDL-C should be considered in the prediction of HT in patients attributable to LAA.

A primary advantage of this study is that a relatively large number of AIS patients were enrolled from the Nanjing city; additionally, the training cohort was from a prospective consecutive hospital-based stroke registry in Nanjing First Hospital. Another advantage is the construction of a nomogram including TG/HDL-C, which accurately predicted the incidence of HT in patients with AIS attributable to LAA. Several limitations should be acknowledged regarding the interpretation of these results. For example, patients with AIS attributable to LAA were only enrolled in the test cohort, and these patients were not from a prospective consecutive hospital-based stroke registry. Additionally, we do not know whether dynamic changes of TG/HDL-C during treatment influence the incidence of HT in patients attributable to LAA. The underlying molecular mechanisms of low TG/HDL in HT should be deeply explored in further studies.

In conclusion, the present study suggests that low levels of TG/HDL-C may be related to an increased risk of HT in LAA, but not in cardioembolism. The negative association between TG/HDL-C and HT should be considered in the management of ischemic stroke attributable to LAA.

MATERIALS AND METHODS
=====================

Study population and study protocol
-----------------------------------

The present study was approved by the Nanjing Medical University Ethics Committee and complied with the Declaration of Helsinki. All of the patient data were acquired from Nanjing First Hospital, Nanjing Medical University between January 2012 and June 2018 and from the Affiliated ZhongDa Hospital of Southeast University between January 2011 and January 2017. The patients were divided into two cohorts, including training and test cohorts. The clinical characteristics of the training and test cohorts are summarized in [Tables 1 and 3](#t1){ref-type="table"}[](#t3){ref-type="table"}. A total of 1423 AIS patients who were retrospectively collected from a prospective consecutive hospital-based stroke registry in Nanjing First Hospital were enrolled in the training cohort. An additional 558 AIS patients attributable to LAA who were admitted to the Affiliated ZhongDa Hospital of Southeast University were retrospectively recruited for the test cohort. Individual patients were enrolled in this study if they met the following conditions: (1) first ictus of stroke; (2) admission within 7 days of stroke onset; (3) blood sample extraction within 24 hours on admission (all enrolled patients had fasting lipid levels drawn the morning after hospital admission); (4) ischemic stroke; (5) had not received thrombolytic therapy with tPA and (6) standard in-house procedures were followed \[[@r15]\]. Several patients were excluded as described in our previous study \[[@r15]\].

A multiset and hospital-based study was conducted to explore the precise effect of serum lipid levels on HT after ischemic stroke. Briefly, the association between serum lipid levels and HT was initially investigated in the training cohort. We found a significant association of serum lipid levels and HT in patients with AIS attributable to LAA by using a logistic regression model. Furthermore, we also constructed a prognostic model to predict the incidence of HT in AIS patients attributable to LAA. For the test cohort, we further confirmed the influence of serum lipid levels on HT in a total of 558 patients with AIS attributable to LAA, and we validated the prognostic model in another independent cohort.

Clinical and laboratory assessments
-----------------------------------

All patients underwent initial brain computed tomography (CT) or magnetic resonance imaging (MRI) before the initiation of antithrombotic therapy within 24 hours after admission. Subsequently, these patients underwent CT or MRI within 7 days after hospital admission or with any worsening. All CT or MRI scans were performed by a neuroradiologist blinded to the baseline characteristics and progress of AIS patients. The protocol of the MRI scan consisted of axial diffusion-weighted imaging (DWI), fluid-attenuated inversion recovery (FLAIR), and axial gradient echo (GRE) sequences. HT was defined as a high-density shadow within the area of low attenuation on the follow-up CT scan or a low-signal area within the acute ischemic lesion on the follow-up GRE sequences of the MRI scan. HT was confirmed according to the European Cooperative Acute Stroke Study I (ECASS I) \[[@r31]\]. As symptomatic HT and asymptomatic HT are part of the same continuum and their discriminatory criteria are somewhat inaccurate, all HTs were considered independently of their clinical symptoms. Stroke etiology and stroke severity were determined as described in our prior study \[[@r32]\].

The baseline characteristics extracted on admission included (1) demographics (sex, age, weight and height), (2) clinical characteristics (smoking, admission blood pressure and NIHSS score), (3) medical history (hypertension, diabetes mellitus and coronary artery disease, atrial fibrillation and previous TIA), (4) stroke etiology, (5) prior use of antiplatelets (aspirin, clopidogrel and cilostazol) and anticoagulants (warfarin, rivaroxiban and dabigatran), and (6) laboratory characteristics.

Statistical analysis
--------------------

All statistical analyses were performed using SPSS software (Version 20, Chicago, USA) and R 3.0.3 software (Institute for Statistics and Mathematics, Vienna, Austria). The TG/HDL-C was obtained by dividing TG by HDL-C. Categorical variables were expressed as frequencies and percentages and were compared by the Chi-squared test. Continuous variables were expressed as the means ± standard deviations (S.D.) or medians (interquartile ranges, IQR), which were compared by the Student's t test, one-way ANOVA or the Mann--Whitney U-test if necessary. The discriminatory power of serum lipid levels was assessed by receiver operating characteristic (ROC) curves and corresponding area under the ROC curve (AUC). Comparisons of the AUCs of serum lipid levels were performed by nonparametric statistics \[[@r33]\]. Univariable logistic regression analyses were applied with HT as the dependent variable to obtain odds ratios (ORs) and corresponding 95% confidence intervals (CIs) of HT by serum lipid levels. Significant variables in the univariate analyses were selected into the multivariable logistic regression model to acquire independent predictors. Furthermore, a nomogram based on the independent predictors was constructed by R software with the package *rms*. The predictive capacity of the nomogram was determined by Harrell's c-index. *P*\<0.05 was regarded as statistically significant.
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